Why is CVS Health stock sliding today?

CVS Health stock slipped 0.9% in pre-open trading today after the company released its third-quarter 2026 results before the bell and simultaneously confirmed a sweeping plan to break up its integrated healthcare business into two separate publicly traded entities. Despite reporting revenues of $108.4 billion — up 5.4% year-over-year — and an adjusted EPS of $2.09, well above the Wall Street consensus of approximately $1.65, the stock failed to hold the gains that had built up in the prior session on breakup speculation.

The corporate split announcement, which would separate CVS’s roughly 9,000 retail pharmacies from its Aetna insurance arm and Caremark pharmacy benefit management operations — potentially by 2028 — marks a dramatic reversal of the integrated strategy that defined the company’s 2018 acquisition of Aetna. While BofA Securities and Barclays both reiterated Buy ratings on the stock, investors appear to be weighing the complexity and multi-year execution risk of the separation against the near-term earnings strength. Adding to the caution, Aetna’s Medicare Advantage star ratings for 2027 showed a meaningful decline, with roughly 70% of members in four-star-or-better plans compared to 81% previously — a headwind analysts estimate could translate into hundreds of millions of dollars in lost bonuses. Ongoing 340B drug-pricing reimbursement pressure and concerns about Caremark client retention further clouded the outlook.

The broader market backdrop offered little explanation for CVS’s weakness, with the S&P 500 gaining nearly 1.0%, the Dow Jones rising approximately 1.4%, and the Nasdaq advancing roughly 0.9% — underscoring that today’s CVS move is driven by company-specific dynamics rather than macro forces. The company also raised its full-year 2026 guidance, lifting its adjusted EPS outlook to at least $8.20 and increasing its cash flow from operations target to at least $15.5 billion.

Taken together, the pre-market softness reflects a classic "sell the news" dynamic: the earnings beat and breakup confirmation had been partially anticipated after Tuesday’s after-hours surge on initial split reports, leaving the stock vulnerable to profit-taking as investors shift focus to the long road ahead in executing one of the largest corporate separations in U.S. healthcare history.